<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02643719</url>
  </required_header>
  <id_info>
    <org_study_id>14-01981</org_study_id>
    <nct_id>NCT02643719</nct_id>
  </id_info>
  <brief_title>Migraine Treatment in ED</brief_title>
  <official_title>Evaluation of a Behavioral Program for Migraineurs in the Emergency Department.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized pilot feasibility study evaluating the impact of introducing behavioral treatment
      for migraine in the Emergency Department (ED) and prescribing migraine preventive medications
      in the ED. The study will examine the effect of these treatments, both individually and in
      combination, on pain severity and headache-related disability. This study is designed to
      examine the feasibility of comparing four interventions for ED patients presenting with
      migraine. Group 1: Starting topiramate; Group 2: Doing a brief behavioral intervention; Group
      3: Treating with combination therapy of topiramate and behavioral intervention; and Group 4:
      Standard of Care.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study team missed continuing review and study lapsed with out recruiting any subjects.
  </why_stopped>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Verbal numeric rating scale (VNRS) scores</measure>
    <time_frame>24 hours, 72 hours</time_frame>
    <description>To examine whether there is a significant pain reduction for patients in the ED after behavioral therapy, investigators will analyze pain scores in the ED, and at 24 hours and 72 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Headache Impact Test (HIT) scores</measure>
    <time_frame>3 Months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Behavioral intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>topiramate and behavioral intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Relaxation Therapy</intervention_name>
    <description>Between 30-60 minutes after the standard of care medication administration (metoclopramide, magnesium, prochlorperazine, ketorolac, or steroids at discretion of treating physician), patient receives training in relaxation therapy.</description>
    <arm_group_label>Behavioral intervention</arm_group_label>
    <arm_group_label>topiramate and behavioral intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <description>Preventive medication prescriptions given to the patient along with written instructions and information about side effects:
Topiramate 25mg tabs (with a plan to increase to 100mg)</description>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_label>topiramate and behavioral intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard discharge instruction sheet plus standard of care medication as prescribed by treating physician. The clinical team will be instructed to address post-discharge care as appropriate</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abortive Medication (Naproxen and Sumatriptan)</intervention_name>
    <description>All participants will receive abortive medication for acute treatment of their migraine. Preferred medications are Naproxen (500mg) and Sumatriptan (100mg)</description>
    <arm_group_label>Behavioral intervention</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_label>topiramate and behavioral intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 years to 65 years of age

          -  primary diagnosis of migraine based on the International Classification of headache
             disorders 3 beta criteria

          -  having a migraine 3 or more days/month.

        Exclusion Criteria:

          -  Cognitive Behavioral Therapy (CBT), biofeedback or other relaxation therapy in the
             past year

          -  being on medication used for migraine prevention (topiramate, propranolol, valproic
             acid, amitriptyline/nortriptyline/imipramine/desipramine, botulinum toxin, a SNRI,
             angiotensin-converting enzyme inhibitors (ACE-I) or ARB)

          -  cognitive deficit or other physical problem with the potential to interfere with
             behavioral therapy

          -  substance or alcohol abuse as determined by self-report or prior documentation in the
             medical record.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mia Minen</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University Medical School</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>December 29, 2015</study_first_submitted>
  <study_first_submitted_qc>December 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <last_update_submitted>August 22, 2018</last_update_submitted>
  <last_update_submitted_qc>August 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>migraine</keyword>
  <keyword>topiramate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

